CORDIS
EU research results

CORDIS

English EN

Light-based functional in vivo monitoring of diseases related enzymes

Project information

Grant agreement ID: 241919

Status

Closed project

  • Start date

    1 November 2009

  • End date

    30 April 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 6 867 435,87

  • EU contribution

    € 4 850 785

Coordinated by:

INSTITUT JOZEF STEFAN

Slovenia

Objective

LIVIMODE aims to develop specific tools for non invasive in vivo imaging of disease related molecular events. Such tools are of high relevance for disease detection, staging, developing animal models of human disease, and evaluating novel therapies. We propose to use optical imaging, which is optimally suited for this task as it provides excellent sensitivity and allows visualizing molecular events via a fluorescent signal. While optical imaging technology has rapidly evolved over the last years, the availability of SMART (activatable) imaging agents that change their fluorescence properties upon disease related events, remains a critical gap. The LIVIMODE project proposes to combine expertises in medicinal chemistry, pharmacology and imaging in a conceptually new approach in designing SMART agents. In particular, we will (i) translate established strategies in medicinal/pharmaceutical chemistry to design highly selective SMART probes and (ii) optimize the cell/tissue specificity of probes integrating concepts from polymer and protein based targeted drug delivery. We will generate a toolset of highly selective targeted SMART probes for at least 10 disease-relevant proteases. The selection of target proteases is based on their relevance in disease processes that cannot yet be monitored with non invasive technology. These include (i) the development of tumor microenvironment as a critical factor in oncogenesis, (ii) tumor hypoxia and angiogenesis, and (iii) inflammatory and degenerative processes in osteoarthritis. LIVIMODE has established animal models for these conditions and will use in vivo optical imaging to evaluate the novel SMART probes as tools for monitoring disease progression and drug efficacy. This will enhance our knowledge of disease mechanisms and our ability to rapidly characterize drug candidates for in vivo efficacy (proof-of-efficacy). Selected SMART probes will be optimized to assess their potential as clinical diagnostics.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT JOZEF STEFAN

Address

Jamova 39
1000 Ljubljana

Slovenia

Activity type

Research Organisations

EU Contribution

€ 784 925

Administrative Contact

Jadran Lenarcic (Prof.)

Participants (10)

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 1 089 040

UNIVERSITAT AUTONOMA DE BARCELONA

Spain

EU Contribution

€ 319 899,60

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 92 909,71

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

EU Contribution

€ 170 000

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

EU Contribution

€ 45 000

FREIE UNIVERSITAET BERLIN

Germany

EU Contribution

€ 510 600

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 383 864

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 844 222,40

FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE

Spain

EU Contribution

€ 302 850

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 307 474,29

Project information

Grant agreement ID: 241919

Status

Closed project

  • Start date

    1 November 2009

  • End date

    30 April 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 6 867 435,87

  • EU contribution

    € 4 850 785

Coordinated by:

INSTITUT JOZEF STEFAN

Slovenia